Grants and Contracts Details
Description
With the increasing development of antimicrobial resistance to traditional antibiotics, new
technologies are needed to combat infections that cause human disease. Oral infections are rarely
life threatening but have a significant impact on quality of life, economics, and oral and systemic
health. The use of systemic antibiotics for the management of oral infections, especially in cases
of the biofilm-associated diseases dental caries and periodontal disease, has not received
considerable support because of the implications for the emergence of antibiotic resistance in
medically important pathogens. However, the use of topical chemotherapeutic agents is gaining
considerable support but the development of such agents is lagging behind the potential
applications.
This proposal brings together experienced investigators from the fields of molecular virology,
molecular microbiology, and engineering in an attempt to develop a new approach to controlling
oral infections. The use of antimicrobial peptides for oral infection has been considered
previously, especially the use of host-derived peptides. However, this proposal introduces a new
group of antimicrobial peptides of viral origin that utilize the lytic domains of membrane active
viruses. Referred to as the lentiviral lytic peptide (LLP), this 28-residue peptide is similar in
character .to the magainins and human cathelicidins. Engineered LLP derivatives (eLLPs) have
been developed that are highly effective for in vitro killing of bacterial pathogens.
We hypothesize that topical application of eLLPs may represent an exciting new approach to the
treatment of oral infections. This proposal outlines in vitro studies that are necessary prior to
evaluating the eLLPs in animal models of oral disease. Being a new area of research, this
proposal is "high risk" since no previous in vivo data exists to support this approach. However,
based on our preliminary in vitro studies, this approach may have tremendous applications in the
control of oral infections and may be of "high impact" if proven effective in a test model.
Status | Finished |
---|---|
Effective start/end date | 11/1/03 → 10/31/04 |
Funding
- KY Science and Technology Co Inc: $15,000.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.